SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

VISTA PHARMACEUTICALS

BSE: 524711 29 Sep 2025
Healthcare
₹ 9.95
Vista Pharmaceuticals Ltd. specializes in Pharmaceuticals within the Healthcare sector.

VISTA PHARMACEUTICALS - Share Price & Details

Market Cap
₹70.4
High /Low
16.6 / 9.1
Stock P/E
NA
Book Value
₹12.3
Dividend Yield
0.0
ROCE
-8.55
ROE
₹-10.8
Face Value
2.0
PEG Ratio
NA
EVEBITDA
₹-21.5
Debt
7.40
CMP / FCF
-13.1
Debt to equity
₹0.16
NP Ann
-4.65
High price all time
56.2
Piotroski score
₹3.0
Graham Number
NA
No. Eq. Shares
6.16
Net CF
₹0.64
Net profit
-4.65
Price to book value
0.93
Interest Coverage
₹-4.51
Low price all time
0.41
Industry PE
33.8
Reserves
₹33.1
Free Cash Flow
₹-7.42

Broker Recommendations

No broker recommendations available

We couldn’t find any recent recommendations for this company (matched by symbol or BSE code). Please check back later.


Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
FABINO ENTERPRISES LIMITEDNANANANA5.0984.8
Triochem Products Ltd.,NANANANA0
VISTA PHARMACEUTICALS LTD.NANANANA70.4
WELCURE DRUGS & PHARMACEUTICALNANANANA68.22.46
BIOFIL CHEMICALS & PHARMACEUTI92.6524.1164.331.4867.624.2

Peer Comparison Chart


About VISTA PHARMACEUTICALS

Vista Pharmaceuticals Ltd., with Security Code 524711, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Order Book


Latest News

What drives CRBD stock price - Stock Split Announcements & Multiply Your Assets With Time-Tested Picks

(27 Sep 2025)
【Stock Watchlist】✌️ Receive comprehensive market analysis from seasoned professionals, including live updates on stock indices, commodities...
Read more →

KalVista Pharmaceuticals Experiences Evaluation Revision Amidst Mixed Market Signals

(24 Sep 2025)
KalVista Pharmaceuticals, Inc. has recently revised its evaluation amid changing market conditions. The stock is priced at $13.62,...
Read more →

First-Ever Oral HAE Attack Treatment: KalVista's EKTERLY Secures Major EU & Swiss Regulatory Win

(20 Sep 2025)
EKTERLY, first oral on-demand treatment for hereditary angioedema, approved in EU & Switzerland. German launch Q4 2025.
Read more →

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Buy" from Analysts

(15 Sep 2025)
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have been assigned a consensus rating of "Buy" from the nine...
Read more →

Needham & Company LLC Reiterates Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV)

(15 Sep 2025)
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report)'s stock had its "buy" rating restated by analysts at Needham & Company LLC in a...
Read more →

KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Raised to $28.00

(15 Sep 2025)
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) had its target price raised by stock analysts at JMP Securities from $27.00 to...
Read more →